CD19 and neoplasm: This point-of-care technology can even be optimized by co-expression of a safety switch and a membrane-bound version of interleukin-15 (mbIL15) to enhance safety and in vivo persistence and demonstrated anti-tumor activity against CD19+ tumors and prolonged T cell survival in mouse models (96).